Results 61 to 70 of about 31,914 (284)

How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?

Journal of Education, Health and Sport, 2017
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs).
Łukasz Wołowiec, Joanna Banach, Daniel Rogowicz, Magdalena Węglarz, Walery Zukow, Władysław Sinkiewicz   +5 more
doaj   +3 more sources

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]

, 2017
Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core   +1 more source

Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage

Journal of the Formosan Medical Association, 2020
Background: The application of non-vitamin K antagonist oral anticoagulant (NOAC) reduces the risk of intracerebral hemorrhage (ICH) in comparison with vitamin K antagonist (VKA).
Szu-Ju Chen, Shin-Joe Yeh, Sung-Chun Tang, Shin-Yi Lin, Li-Kai Tsai, Jiann-Shing Jeng   +5 more
doaj   +1 more source

Prevention of thromboembolic complications in patients with atrial fibrillation and obesity

Annales Academiae Medicae Silesiensis, 2023
Atrial fibrillation (AF) is an arrhythmia that occurs in 1–2% of the population. Chronic oral anticoagulation is recommended in the group of patients with AF to prevent thromboembolic complications. Obesity is a factor contributing to the development and
Izabela Kolasa, Beata Średniawa
doaj   +1 more source

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. [PDF]

, 2015
Patients at thromboembolic risk with non-valvular atrial fibrillation (AF) can now be managed either with a vitamin K antagonist (VKA) or with a fixed dose of a non-VKA oral anticoagulant (NOAC), while patients with valvular AF have been restricted to ...
De Caterina, R, John Camm, A
core   +1 more source

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation

Clinical Research in Cardiology, 2022
Background The effects of left atrial appendage (LAA) occlusion compared to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in patients with atrial fibrillation (AF) remain unknown.
W. Ding, J. Rivera‐Caravaca, Elnara Fazio-Eynullayeva, P. Underhill, D. Gupta, F. Marín, G. Lip   +6 more
semanticscholar   +1 more source

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice : systematic review and economic evaluation [PDF]

, 2015
Funding The National Institute for Health Research Health Technology Assessment programme.Peer reviewedPublisher ...
, , , , , , , , , , , , , , , , , , , , Ahmad, Ansell, Ascione, Azarnoush, Bauman, Bauman, Bauman, Bayer, Bereznicki, Bloomfield, Braun, Briggs, Bronnum-Hansen, Brown, Cayley, Christensen, Christensen, Christensen, Christensen, Christensen, Christensen, Connock, Connolly, Cromheecke, Curtis, Dauphin, DeWilde, Dorman, Drummond, Dunning, Edwards, Eitz, Fitzmaurice, Fitzmaurice, Fitzmaurice, Friberg, Friberg, Fuster, Gadisseur, Gadisseur, Gailly, Gallagher, Garcia-Alamino, Gardiner, Gardiner, Go, Hallan, Havrda, Hemkens, Heneghan, Heneghan, Hentrich, Higgins, Hobbs, Horstkotte, Horstkotte, Horstkotte, Hylek, Jackson, Jones, Jones, Jowett, Kannel, Khan, Kind, Kitchen, Koertke, Koertke, Koertke, Kvidal, Körtke, Körtke, Lafata, Lee, Marini, Matchar, Matchar, Matchar, McCahon, Menéndez-Jándula, Moher, Moon, Muller, Murray, Paioni, Pollack, Rasmussen, Regier, Robinson, Rose, Ruel, Ryan, Ryan, Ryan, Saka, Sawicki, Sawicki, Schmidt, Sidhu, Siebenhofer, Siebenhofer, Slot, Sobieraj-Teague, Sola-Morales, Soliman Hamad, Spackman, Sudlow, Sullivan, Sundberg, Sunderji, Sunderji, Taborski, Tamayo, Vahanian, van, Verret, Visnansky, Voller, Völler, Wallentin, Wallentin, Wang, Wardlaw, Wells, Williams, You   +145 more
core   +1 more source

Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study

PLoS ONE, 2017
Background Following their introduction, the non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly prescribed in Asia for stroke prevention in patients with non-valvular atrial fibrillation (AF).
So-Ryoung Lee, E. Choi, Kyungdo Han, M. Cha, Seil Oh, G. Lip   +5 more
semanticscholar   +1 more source

Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention.

Stroke, 2019
Background and Purpose- Despite treatment with oral anticoagulants, patients with nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events.
M. Paciaroni, G. Agnelli, V. Caso, G. Silvestrelli, D. Seiffge, S. Engelter, G. M. De Marchis, A. Polymeris, M. Zedde, S. Yaghi, P. Michel, A. Eskandari, K. Antonenko, S. Sohn, M. Cappellari, T. Tassinari, R. Tassi, L. Masotti, A. Katsanos, S. Giannopoulos, Monica Acciarresi, A. Alberti, M. Venti, M. Mosconi, M. Vedovati, P. Pierini, M. Giustozzi, E. Lotti, G. Ntaios, O. Kargiotis, S. Monaco, P. Lochner, F. Bandini, C. Liantinioti, L. Palaiodimou, Azmil H. Abdul-Rahim, K. Lees, M. Mancuso, L. Pantoni, S. Rosa, P. Bertora, S. Galliazzo, W. Ageno, E. Toso, F. Angelini, A. Chiti, G. Orlandi, L. Denti, Y. Flomin, S. Marcheselli, N. Mumoli, A. Rimoldi, E. Verrengia, E. Schirinzi, M. Del Sette, P. Papamichalis, A. Komnos, Nemanja Popovic, M. Žarkov, A. Rocco, M. Diomedi, E. Giorli, A. Ciccone, B. M. Mac Grory, K. Furie, B. Bonetti, V. Saia, F. Guideri, M. Acampa, G. Martini, E. Grifoni, M. Padroni, Efstathia Karagkiozi, Kalliopi Perlepe, K. Makaritsis, M. Mannino, M. Maccarrone, L. Ulivi, N. Giannini, E. Ferrari, A. Pezzini, B. Doronin, V. Volodina, A. Baldi, Cataldo D’Amore, D. Deleu, F. Corea, J. Putaala, P. Santalucia, K. Nardi, A. Risitano, D. Toni, G. Tsivgoulis   +92 more
semanticscholar   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources